<DOC>
	<DOCNO>NCT02578537</DOCNO>
	<brief_summary>Ticagrelor , new P2Y12 receptor antagonist , achieve faster , consistent high platelet inhibition clopidogrel , consider noticeable patient ACS combine chronic kidney disease ( CKD ) . Nonetheless , pharmacokinetic property ticagrelor patient CKD NSTE-ACS thoroughly study . This study design provide PK PD data ticagrelor compare clopidogrel , order estimate ticagrelor superior clopidogrel get good inhibition platelet patient CKD NSTE-ACS . P2Y12 inhibitor naïve patient CKD ( eGFR &lt; 60 ml/min/1.73m2 ) NSTE-ACS enrol single-center , prospective , randomize , parallel-control study randomly assign one-to-one ratio receive ticagrelor clopidogrel top chronic aspirin treatment . The primary endpoint PRU Verify Now 30 day load dose .</brief_summary>
	<brief_title>COmparison Pharmacodynamics Pharmacokinetics Ticagrelor Versus Clopidogrel Patients With CKD NSTE-ACS</brief_title>
	<detailed_description>Dual antiplatelet therapy aspirin clopidogrel become standard care patient acute coronary syndrome ( ACS ) . However , clopidogrel question insufficient platelet inhibition residual platelet reactivity , especially patient impaired renal function . Ticagrelor , new P2Y12 receptor antagonist , achieve faster , consistent high platelet inhibition clopidogrel , noticeable patient ACS combine chronic kidney disease ( CKD ) . Nonetheless , pharmacokinetic property ticagrelor patient CKD NSTE-ACS , best investigator ' knowledge , thoroughly study . This study design provide PK PD data ticagrelor compare clopidogrel , order estimate ticagrelor superior clopidogrel get good inhibition platelet patient CKD NSTE-ACS . The potential hypothesis evaluate correlation platelet inhibition renal function CYP2C19 gene type patient treat ticagrelor clopidogrel . P2Y12 inhibitor naïve patient CKD ( eGFR &lt; 60 ml/min/1.73m2 ) NSTE-ACS enrol single-center , prospective , randomize , parallel study randomly assign one-to-one ratio receive ticagrelor clopidogrel top chronic aspirin treatment . The primary endpoint PRU Verify Now 30 day load dose .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>P2Y12 inhibitor naïve patient present NSTEACS ( unstable angina nonST segment elevation myocardial infarction ) . Males nonpregnant female &gt; 18 year age . eGFR &lt; 60 ml/min/1.73m2 ( MRDR formula ) . With planned percutaneous coronary intervention ( PCI perform 24 hour load dose ) . Written inform consent provided.Provision inform consent prior study specific procedure . Cardiogenic shock . Thrombolytic therapy administer randomization . Active bleed bleed predisposition , include retinal vitreous hemorrhage , gastrointestinal urinary tract hemorrhage , history intracranial haemorrhage cerebral infarction . Hypersensitivity ticagrelor excipients . Deep puncture major surgery within 1 month . Untreated uncontrolled hypertension blood pressure &gt; 180/110 mmHg . Known hemoglobin &lt; 10 g/dL platelet count &lt; 100 × 109/L . Known moderate severe hepatic impairment . Known aminotransferase level &gt; 3x upper limit normal . Known allergy study drug device ( aspirin , clopidogrel , ticagrelor stainless steel , contrast agent , etc. ) . Pregnancy lactation . Any condition might interfere study compliance , otherwise unsuitable study participation judge investigator . Unwilling unable get repeat platelet assay clinical followup . Unwilling unable provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Ticagrelor</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>NSTE-ACS</keyword>
	<keyword>CKD</keyword>
</DOC>